Zobrazeno 1 - 10
of 103
pro vyhledávání: '"H. B. Muss"'
Autor:
G F P, Aleixo, H, Yu, Y T, Chen, K A, Nyrop, R J, Louie, A M, Deal, S S, Shachar, H B, Muss, G R, Williams
Publikováno v:
Breast cancer research and treatment. 186(2)
Myosteatosis (intramuscular adiposity) is predictive of chemotherapy toxicity in women undergoing adjuvant chemotherapy for breast cancer (BC). We evaluated a novel, user-friendly and cost-effective technique utilizing a Picture Archiving and Communi
Autor:
Chelsea K. Osterman, Grant R. Williams, Tomohiro F. Nishijima, H. B. Muss, Allison M. Deal, K. A. Nyrop, Tucker Brenizer, Hanna K. Sanoff
Publikováno v:
Annals of Oncology. 32:S1187
Autor:
Elizabeth Claire Dees, A. Wood, Lisa A. Carey, KE Reeder-Hayes, H. B. Muss, Allison M. Deal, K. A. Nyrop, Trevor A. Jolly, Seul Ki Choi, Chad W. Wagoner, Jordan T. Lee, Carey K. Anders
Publikováno v:
Breast cancer research and treatment. 168(1)
Ensuring and measuring adherence to prescribed exercise regimens are fundamental challenges in intervention studies to promote exercise in adults with cancer. This study reports exercise adherence in women who were asked to walk 150 min/week througho
Autor:
Elizabeth Claire Dees, Allison M. Deal, Lisa A. Carey, K. A. Nyrop, Seul Ki Choi, William A. Wood, KE Reeder-Hayes, H. B. Muss, Chad W. Wagoner, Jordan T. Lee, Carey K. Anders, Trevor A. Jolly
Publikováno v:
Breast Cancer Research and Treatment. 173:245-245
In the original publication, the sixth author name was published incorrectly as A. Wood. The correct author name should read as W. A. Wood.
Autor:
J W, Eley, H A, Hill, V W, Chen, D F, Austin, M N, Wesley, H B, Muss, R S, Greenberg, R J, Coates, P, Correa, C K, Redmond
Publikováno v:
JAMA: The Journal of the American Medical Association. 272:947-954
To examine the ability of recognized prognostic factors for breast cancer to account for the observed poorer survival in blacks compared with their white counterparts.Subjects included 1130 women (612 blacks and 518 whites) aged 20 to 79 years residi
Autor:
H. B. Muss, J. M. Cruz
Publikováno v:
Annals of Oncology. 3:S15-S20
Summary Progestin therapy has become an established endocrine modality for the treatment of metastatic breast cancer, with medroxyprogesterone acetate and megestrol acetate being the most widely used agents. Both drugs display similar effectiveness a
Publikováno v:
American Journal of Clinical Oncology. 15:494-496
Twenty-one patients with recurrent epithelial ovarian carcinoma not amenable to cure with further surgery or radiotherapy were entered into a Phase II trial utilizing i.v. leucovorin at 20 mg/m2 followed by i.v. 5-fluorouracil at 425 mg/m2 administer
Publikováno v:
Cancer. 89(2)
Etiologic studies of breast carcinoma have indicated that weight, body mass index (BMI), and breast tissue density are important determinants of a woman's risk for the disease. This study looked at the independent effects of these risk factors.Data f
Publikováno v:
Oncology (Williston Park, N.Y.). 14(5)
In 1999, metastatic breast cancer claimed the lives of almost 45,000 women. For the vast majority of patients, metastatic breast cancer is an incurable disease with a median survival of only 2 to 3 years after diagnosis. The major goal of therapy is
Autor:
D R, Budman, D A, Berry, C T, Cirrincione, I C, Henderson, W C, Wood, R B, Weiss, C R, Ferree, H B, Muss, M R, Green, L, Norton, E, Frei
Publikováno v:
Journal of the National Cancer Institute. 90(16)
Both total dose and dose intensity of adjuvant chemotherapy are postulated to be important variables in the outcome for patients with operable breast cancer. The Cancer and Leukemia Group B study 8541 examined the effects of adjuvant treatment using